Navigation Links
Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
Date:5/14/2008

dication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication, and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases, and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

For investor and media inquiries, please contact:

Email: ir@simcere.com

In Nanjing:

Frank Zhao

Chief Financial Officer

Simcere Pharmaceutical Group

Tel: 86-25-8556-6666 ext 8818

In Beijing:

Wu Kejia

Brunswick Group

Tel: 86-10-6566-2256

In Hong Kong

Joseph Lo

Brunswick Group

Tel: 852-3512-5000

In the United States:

Michael Guerin

Brunswick Group LLC

Tel: +1-212-333-3810


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
2. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
3. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
4. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Bulgaria (PRWEB) August 20, 2014 ... was released today including improvements to the enterprise ... and connectors for Lucene, SOLR and Elasticsearch. This ... for this high performance triplestore – GraphDB™ was ... interested in deploying the only mature enterprise resilient ...
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets  has announced ... Global Strategic Business Report" report to their offering. ... Culture Supplies in US$ Thousands by the following Product Segments: Media, ... for the US, Canada , Japan ... , and Latin America . Annual estimates and ...
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Asia-Pacific , and Rest of ... 2012 through 2020. Market data and analytics are derived from ...
(Date:8/19/2014)... 19, 2014 Research and ... the "Spectroscopy Equipment and Accessories - ... their offering. This report ... and Accessories in US$ Thousands by the ... Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) ...
Breaking Biology Technology:Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2
... Jan. 2 Nektar,Therapeutics, (Nasdaq: NKTR ) President ... at the upcoming JPMorgan 26th Annual Healthcare,Conference at the ... January 8, 2008, at 4:30 p.m. Pacific Time., ... and slideshow,webcast through a link posted on the Investor ...
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it has ... Food and Drug Administration (FDA) requesting approval of,TREANDA(R) ... patients,with indolent B-cell non-Hodgkin,s lymphoma (NHL) who have ... rituximab-containing,regimen. According to the National Cancer Institute, an ...
... MYL ) today,announced that Mylan Pharmaceuticals Inc. ... Drug Administration (FDA) for its Abbreviated New Drug,Application ... Balsalazide Disodium Capsules are the generic version of ... approximately,$130.9 million for the 12 months ending Sept. ...
Cached Biology Technology:Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4
(Date:8/20/2014)... from the University of Tbingen, Arizona State University, the ... Public Health Institute (Swiss TPH) isolated Mycobacterium pinnipedii ... least 1000 years old. The pathogen is a relative ... occasionally causes disease in humans today. These researchers assume ... Peruvian coast. "The link to sea lions was unexpected" ...
(Date:8/20/2014)... August 19, 2014 -- Bay Area Lyme Foundation, which ... simple to cure, applauds new research published in an ... Ticks and Tick-borne Diseases . The findings show ... are active throughout the year, making the threat of ... at California Department of Public Health (CDPH) Vector-borne Disease ...
(Date:8/20/2014)... -- When are athletes who have suffered concussions ready ... study has found that high school athletes who head ... days experience a significant regression in their abilities to ... regression, as seen in changes in their balance and/or ... athletes. Ten of the 12 had returned to activity ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... searches blood for the tiniest remnants of broken down ... up cancer activators called proteases. The results improve researchers, ... to where to look for possible indicators of early ... , the research shows previously unknown contributing factors to ...
... The cells and tissues in our bodies grow, develop ... the various microbial pathogens that invade our bodies and ... milieu. Yet the methods of culturing and studying human ... on flat impermeable surfaces. While such 2-D culturing and ...
... with a peer facing the same self-management challenges helped ... sugar levels better than those who used traditional nurse ... University of Michigan Health System. The findings, published ... showed the peer partner program resulted in lower ...
Cached Biology News:New clues to how cancer-related proteins plasmin, thrombin lose inhibition 2New clues to how cancer-related proteins plasmin, thrombin lose inhibition 3New clues to how cancer-related proteins plasmin, thrombin lose inhibition 4The world is not flat: Exploring cells and tissues in three dimensions 2The world is not flat: Exploring cells and tissues in three dimensions 3The world is not flat: Exploring cells and tissues in three dimensions 4Diabetic adults' conditions improved after phone calls with fellow patients 2Diabetic adults' conditions improved after phone calls with fellow patients 3